Professor David Webb holds the Christison Chair of Therapeutics and Clinical Pharmacology at the University of Edinburgh and is a consultant physician and toxicologist at the Royal Infirmary of Edinburgh, running Edinburgh’s Hypertension Excellence Centre.
He undertakes translational research, funded by the British Heart Foundation (BHF), Medical Research Council (MRC) and Wellcome Trust (WT), and runs a research group focused on developing safe and effective medicines for the treatment of hypertension and renal disease. His research involves work in disease models and human subjects. He created Edinburgh’s WT Cardiovascular Initiative, and runs translational medicine and therapeutics (TMAT) programmes for both MRC and WT.
He is Vice-Chair of the Clinical Division of the International Union of Basic and Clinical Pharmacology (IUPHAR), Honorary President of the European Association for Clinical Pharmacology and Therapeutics (EACPT), and President-Elect of the British Pharmacological Society (BPS). He is also a Non-Executive Director of the Medicine and Healthcare products Regulatory Agency (MHRA). In the past, he has been Chair of the Scottish Medicines Consortium (Scottish equivalent of NICE appraisals), President of the Scottish Society of Physicians, and Vice-President of the Royal College of Physicians.
He has been awarded the GSK Silver Medal for research, and the Lilly Gold Medal for contributions to clinical pharmacology, from the BPS, and has been awarded Fellowship of the Royal College of Physicians of London and Edinburgh, the Royal Society of Edinburgh, the Academy of Medical Sciences, the Faculty of Pharmaceutical Physicians, the British Pharmacological Society, the British Hypertension Society, the American Heart Association, and the European Society of Cardiology.